Welcome Exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. Over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. Our first commercial product, COMETRIQ® (cabozantinib), received its initial regulatory approval in late 2012. We are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer. Exelixis In The News Sep 25, 2015 Exelixis Announces Positive Results from METEOR Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma Presented at European Cancer Congress 2015 Sep 25, 2015 European CHMP Adopts Positive Opinion for Cobimetinib in Combination with Vemurafenib for the Treatment of Advanced Melanoma Sep 24, 2015 Exelixis Announces Key Senior Leadership Hires in Medical Affairs, Sales, and Marketing to Support Commercialization of Cabozantinib and Cobimetinib Sep 22, 2015 Exelixis to Host Investor/Analyst Webcast During European Cancer Congress 2015 More News METEOR Results at ECC 2015 Exelixis released positive results for METEOR, the phase 3 pivotal trial of cabozantinib in advanced renal cell carcinoma, at the European Cancer Congress, Sept. 25-29 in Vienna, Austria. View Press Release Listen to Webcast (live Sept. 26, 12:30-2pm EDT; on demand after) View Important Safety Information including Boxed Warning Stock NASDAQ: EXEL Oct 2 2015 4:00pm EDT PRICE: 5.91 +0.18 VOLUME: 4,530,130 SHARES 20 minute delay About Us COMETRIQ® Pipeline Clinical Trials Medical Information Investors & Media Responsibility Careers © Exelixis, Inc. 2015 Website design: Hane Chow, Inc. Privacy Terms of Use